ReportGem ReportGem 中文

TODAY'S MARKET INTELLIGENCE

CanSino: Tetanus Vaccine Receives Drug Registration Certificate from NMPA

Published: 2026-08-20 18:24:04Category: financeHeat: 72

English summary

CanSino Biologics (06185.HK) announced that its adsorbed tetanus vaccine obtained the Drug Registration Certificate (S20260063) from NMPA for non-neonatal tetanus prevention. Phase III data showed superior antibody GMC at 30 days post-vaccination versus control, and an exclusive commercialization agreement with Yuanda Life Sciences has been signed.

The English text is machine translated and may require verification against the Chinese version.

Browse today's intelligence

Related research and intelligence

Inflation Target Challenged, What's Next for ECB?2026-09-01US-Iran escalation on Larak Island keeps oil prices range-bound2026-09-01Escalating Mine Warfare and Island Standoff: Oil Remains Rangebound Amid US-Iran Balance2026-09-01RBNZ September hike to 2.75% nearly certain, October path data-dependent2026-09-01US Treasury Secretary Urges BOJ to Hike Rates; 10-Year JGB Yield Hits 30-Year High2026-09-01Higher U.S. Treasury Yields and Oil Prices Support Dollar; Dollar Index Approaches 99.50, Nonfarm Payrolls Key Catalyst2026-09-01